Nokia stock jumps in New York after Kepler flips to “buy” as earnings loom
7 January 2026
1 min read

Nokia stock jumps in New York after Kepler flips to “buy” as earnings loom

NEW YORK, Jan 7, 2026, 12:25 EST — Regular session

  • Nokia’s U.S.-listed shares rose nearly 6% after Kepler Cheuvreux upgraded the stock to “buy”.
  • Kepler lifted its target price to 6.60 euros, pointing to a sales and margin recovery.
  • Investors now look to Nokia’s Jan. 29 results for 2026 guidance and cash-flow signals.

Nokia Oyj’s U.S.-listed shares climbed 5.9% to $6.86 in midday trade on Wednesday after Kepler Cheuvreux upgraded the Finnish telecom equipment maker to “buy,” according to StreetInsider. 1

The call landed after a roughly 15% pullback from recent highs, which Kepler said had opened a better entry point. The broker raised its target price to 6.60 euros from 5 euros and called Nokia’s valuation “rather reasonable” at about 13 times its 2026 estimated EBIT — earnings before interest and taxes. 2

That matters now because Nokia is heading into its next results with investors still split on whether the network gear market has finally steadied after a bruising downcycle. Nokia is due to report fourth-quarter and full-year 2025 figures on Jan. 29, with attention on its 2026 outlook, adjusted operating margin and free cash flow — cash left after capital spending. 3

In Helsinki, Nokia shares were last indicated up about 3.7% at 5.77 euros. 4

Kepler said the network equipment market stabilised after a 2023-24 contraction driven by inventory cuts and a tougher spending backdrop, and it flagged Nokia’s push in network infrastructure as a key swing factor. The broker also pointed to cost savings already booked and said the company’s AI and cloud-related order intake in network infrastructure has been building.

Nokia has been reshaping its story around network infrastructure and AI-linked demand as operators slow some 5G rollouts, while it absorbs the optical-networking push it gained through its Infinera deal. 5

But the upgrade comes with familiar risks: a slower-than-expected rebound in carrier spending, pricing pressure in mobile networks, and execution risk on margins if cost cuts or integration benefits slip. Any wobble in 2026 guidance could pull focus back to the parts of the business still exposed to patchy telecom capex.

Stock Market Today

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

7 February 2026
New York, Feb 7, 2026, 09:34 EST — Market closed. Alphabet’s non-voting Class C shares (GOOG) closed down 2.48% at $323.10 on Friday, extending a pullback after the Google parent flagged a sharp jump in spending tied to artificial intelligence. 1 With U.S. markets shut for the weekend, the near-term test is whether investors keep treating Big Tech’s AI build-out as a cost problem before it becomes a growth story. A Reuters review of the week’s trading showed fresh jitters around 2026 outlays across the sector, and SanJac Alpha chief investment officer Andrew Wells said the AI trade “got too
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Uber stock gains as CES robotaxi testing update puts autonomy back in focus
Previous Story

Uber stock gains as CES robotaxi testing update puts autonomy back in focus

Mastercard stock rises as Morgan Stanley flags cross-border strength ahead of U.S. jobs report
Next Story

Mastercard stock rises as Morgan Stanley flags cross-border strength ahead of U.S. jobs report

Go toTop